NCT03540615View on ClinicalTrials.gov

BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 28, 2018

Primary Completion Date

February 5, 2019

Study Completion Date

August 1, 2019

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

BAY1830839

Dose escalation in healthy male subjects

DRUG

Placebo

Matching placebo

Trial Locations (1)

13353

CRS Clinical Research Services Berlin GmbH, Berlin

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY